European Association of Urology 27th Meeting of the EAU Section of Urological Research 2021
Format:5 videos + 1 pdf, size: 26.7 GB
Course Audience: urology physician
Day 1 Room 1 (Video MP4 Format)
Day 1 Room 2 (Video MP4 Format)
Day 2 Room 1 (Video MP4 Format)
Day 2 Room 2 Part 1 (Video MP4 Format)
Day 2 Room 2 Part 2 (Video MP4 Format)
ESUR21 – 27th Meeting of the EAU Section of Urological Research (PDF Format)
***Detail:
Friday 8 October 2021
12:00 – 12:02 Welcome – Chairs K. Junker, Homburg (DE) G. Van Der Pluijm, Leiden (NL)
12:02 – 12:40 Session 1: Patient-derived and Humanized Models for Translational Cancer Research – Chairs G. Van Der Pluijm, Leiden (NL) H.Y. Leung, Glasgow (GB)
12:02 – 12:20 Humanized PDX models of immuno-oncology – R. Gareus, (DE)
12:20 – 12:40 GPS for biology; imaging and profiling of FFPE fixed tissue samples – D. Mustafa, Rotterdam (NL)
12:40 – 13:20 EAU Research Foundation: Awardees
12:40 – 12:50 Introduction – G. Jenster, Rotterdam (NL)
12:50 – 13:05 2018 Establishment Penile Cancer Patient-derived Xenograft in Nude Urologist – M. Albersen, Leuven (BE)
13:05 – 13:20 Role of primary tumor in metastatic prostate cancer mouse model Urologist – J. Linxweiler, Homburg/saar (DE)
13:20 – 13:50 Presentations selected from abstracts 1 – Chairs G. Van Der Pluijm, Leiden (NL) H.Y. Leung, Glasgow (GB)
O07 Development of novel prostate cancer patient-derived models and applications for translational research – R. Servant, Basel (CH)
O09 Mutant reovirus with oncolytic and immune-modulatory effects in human and murine prostate cancer models – T.J.A. Janssen, Leiden (NL)
O02 Adrenal glands promote sclerotic progression of castration resistant prostate cancer in vivo – M. Hagberg Thulin, Gothenburg (SE)
14:10 – 15:10 Poster Session 1 – Chairs K.A. Tasken, Oslo (NO) I. Ahmad, Glasgow (GB)
P12 Influence of patient-derived fibroblasts on prostate cancer tumorigenesis in-vitro – A. Tagat, Homburg (DE)
P16 The in vitro activity of Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma – A. Zaccagnino, Homburg/Saar (DE)
P20 Testicular disorders’ awareness and knowledge among Portuguese high-school students Urologist – R. Catarino, Maia (PT)
P24 Integrating analysis of the expression of IDO1 and TDO2 in bladder cancer Pathologist – T. Nguyen, Ho Chi Minh (VN)
P27 Urinary retention as prognostic factor of short-term response to treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
14:25 – 14:30 Discussion
P09 Study of the effect of Erythropoietin on the kidney graft quality; an experimental animal model for kidney grafts preservation before transplantation Urologist – Z. Kratiras, Agria – Volos (GR)
P08 Study of the effect of Sildenafil on the kidney graft quality; an experimental animal model for kidney grafts preservation before transplantation Urologist – Z. Kratiras, Agria – Volos (GR)
P05 The effect of intravesical tarantula cubensis extract on inflamation in interstitial cystitis rat model A. Akdağ, Aydın (TR)
P28 Neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer Urologist – R. Catarino, Maia (PT)
P07 The possible role of CernitinTM therapy in a model of painful bladder syndrome induced by cyclophosphamide in rats N. Dizeyi, Malmo (SE)
14:42 – 14:47 Discussion
P14 Mechanisms of epithelial mesenchymal transition by TGF-ß and LXRs in metastatic prostate cancer E. Bouchareb, Clermont-Ferrand (FR)
P19 Zero-ischemic and sutureless partial nephrectomy by using microwave surgical device: Initial results in canine models Urologist – N.H. Nguyen, Ho Chi Minh city (VN)
P25 Promising benefits of cold atmospheric plasma-based therapies against bladder cancer L. Fernandes, Coimbra (PT)
P13 Artesunate inhibits the progressive growth behavior of docetaxel-resistant prostate cancer cells E. Jüngel, Mainz (DE)
P01 The changes of prostatic microvessel density in Sprague-Dawley rats after castration under the effect of estrogen/androgen at different concentrations B. Wang, Guiyang (CN)
14:59 – 15:04 Discussion
15:10 – 15:50 Session 2: Mechanisms of Tumor Progression and Therapy Resistance Chairs C. Jeronimo, Porto (PT) J. Ceraline, Illkirch (FR)
15:10 – 15:30 Oncometabolites: OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation H. Klocker, Innsbruck (AT)
15:30 – 15:50 Cancer’s nerves H. Hondermarck, Callaghan (AU)
15:50 – 16:50 Presentations selected from abstracts 2 Chairs C. Jeronimo, Porto (PT) J. Ceraline, Illkirch (FR)
O11 Cabazitaxel activity and related metabolic changes in RB1 mutated prostate cancer models M. Marin Aguilera, Barcelona (ES)
O06 Depletion of ribosomal 2’-O-methylation at 28S-Gm4593 mediated by snoRNA
SNORD78 reduces the aggressive phenotype of prostate cancer D. Barros-Silva, Porto (PT)
O01 miRNA expression profiling in different histological subtypes in penile squamous cell carcinoma H. Ayoubian, Homburg (DE)
O10 Small-molecule inhibitors of the Serum Response Factor in combination with enzalutamide: New strategy to treat castrate-resistant prostate cancer M. Prencipe, Dublin (IE)
O03 Activation of the aggressive migrational phenotype in prostate cancer cells invading the perineural space Urologist – A. Sachdeva, Manchester (GB)
O14 Gene expression and coexpression analysis of the entire bladder cancer clinical stage spectrum R. Stroggilos, Athens (GR)
16:50 – 17:10 Journal impact factor, h-index and other metrics: advantage or obstacle of high-quality research
16:50 – 17:10 M. Menger, Homburg/Saar (DE)
Saturday 9 October 2021
09:15 – 09:20 Welcome Chairs K. Junker, Homburg (DE) G. Van Der Pluijm, Leiden (NL)
09:20 – 09:40 Session 3: New Developments in Pathology Chairs A. Vlahou, Athens (GR) M. Colecchia, Milan (IT)
09:20 – 09:40 Prostate Cancer Grading beyond Gleason Score Pathologist – G. Van Leenders, Rotterdam (NL)
09:40 – 10:40 Presentations selected from abstracts 3 Chairs M. Colecchia, Milan (IT) A. Vlahou, Athens (GR)
O04 Digital interferometric polarimetry of the polycrystalline structure for differential diagnosis of prostate tumors Urologist – L. Tryfonyuk, Rivne (UA)
O15 Anti-tumour and immune stimulatory effects in bladder cancer of oncolytic reoviruses R124 and mutant jin-3 G. Van Der Horst, Leiden (NL)
O12 IFNγ-mediated stimulation of PD-L1 expression on extracellular vesicles from renal cell carcinoma cell lines and their effects on CD8+ T cells G. Jaschkowitz, Homburg/Saar (DE)
O13 CD39 and CD73 expression on T cells and tumor cells in bladder cancer Urologist – F. Teixeira Gabriel Furriel, Coimbra (PT)
O08 A survey of current trends in urinary extracellular vesicle research E.S. Martens-Uzunova, Rotterdam (NL)
O05 The role of LncRNA NAALADL2-AS2 in the development of castration resistant prostate cancer L.N. Groen, Nijmegen (NL)
11:00 – 12:05 Session 4: Novel immunotherapic approaches and treatment combinations Chairs I. Heidegger, Innsbruck (AT) A. Masson-Lecomte, Paris (FR)
11:00 – 11:20 Promising strategies in immune-oncology N. van Montfoort, ()
11:20 – 11:44 Combination therapies in renal carcinoma: Synergism or “just” addition? K. Junker, Homburg (DE) E. Nossner, Munich (DE)
11:44 – 12:05 Panel Discussion Panel K. Junker, Homburg (DE) E. Nossner, Munich (DE) N. van Montfoort, Leiden (NL) I. Heidegger, Innsbruck (AT) A. Masson-Lecomte, Paris (FR)
12:30 – 13:30 Poster Session 2 – Chairs Urologist – J. Linxweiler, Homburg/saar (DE) E.S. Martens-Uzunova, Rotterdam (NL)
P21 Increased expression of Cyclin D 1 as a biomarker in transitional cell carcinoma: A noninvasive approach
P10 Interim results from a multicentre clinical trial evaluating a drop-in gamma probe for sentinel lymph node dissection in prostate cancer – C. Solà Marqués, Barcelona (ES)
P17 PD-L1 expression on extracellular vesicles in renal cell carcinoma patients Urologist – P. Zeuschner, Homburg (DE)
P02 Genome-wide compound heterozygote analysis highlights DPY19L2 alleles in a non-consanguineous Spanish family with a complete form of globozoospermia – L. Bossini-Castillo, Granada (ES)
P11 Development of Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) criteria for reporting adverse events during surgical procedures and evaluating their impact on the post-operative course – T. Sholklapper, Baltimore (US)
12:45 – 12:50 Discussion
P23 Specific miRNA patterns characterize the invasion capability of pT1G3 tumors of the bladder – S. Rau, Homburg/Saar (DE)
P06 Could the soluble form of VEGFR1 be used as a biomarker and therapeutic target for BPS/IC? Urologist – P. Abreu-Mendes, Figueira da Foz (PT)
P29 Immunological status of bladder cancer patients based on urine leukocyte composition at radical cystectomy – O. Rodriguez Faba, Barcelona (ES)
P15 Pathological correlation between prostate biopsies and the radical prostatectomy specimen: A review of 30 cases Urologist – S. A Aboubakry, Nouakchott (MR)
P03 The potential use of medical grade Manuka honey in the treatment of interstitial cystitis/bladder pain syndrome – M. Yusuh, Southampton (GB)
13:02 – 13:07 Discussion
P18 Tumor-specific proteins on extracellular vesicles as potential biomarkers in renal cell carcinoma – D. Himbert, Homburg (DE)
P04 Could early in life stressful events induce a specific bladder pain phenotype inadult female mice? Urologist – P. Abreu-Mendes, Figueira da Foz (PT)
P26 A large pilot study on the diagnostic performance of electronic nose in detectingBladder Cancer
13:13 – 13:18 Discussion
13:30 – 13:40 Wrap-up, announcements and closure of the meeting – Chair K. Junker, Homburg (DE)